Molecular modeling and structure-activity relationship of podophyllotoxin and its congeners

Journal of Biomolecular Screening

Volumn 15, Issue 5, 2010, Pages 528-540

  Naik, Pradeep Kumar ^a   Alam, Afroz ^a   Malhotra, Ashutosh ^a   Rizvi, Owasis ^b  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b Scube Scientific Software   (India)

Author keywords

Cytotoxicity; Drug screening; Model validation; Podophyllotoxin; Quantitative structure activity relationship

Indexed keywords

ISOXAZOLIGNAN DERIVATIVE; PODOPHYLLOTOXIN DERIVATIVE; PYRAZOLIGNAN DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG STRUCTURE; GENETIC ALGORITHM; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PODOPHYLLOTOXIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953648640     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110368994     Document Type: Article

References (29)

1. Jardine I.: Anticancer agents based on natural product models. In Cassady JM, Douras JD (eds): Medicinal Chemistry Monographs. New York: Academic Press, 1980: 319-351.
2. Savel H.: The metaphase-arresting plant alkaloids and cancer chemo therapy. Prog Exp Tumor Res 1966 ; 8: 189-224.
3. Sackett DL: Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchine site of tubulin. Pharm Ther 1993 ; 59: 163-228.
4. Damayanthi Y., Lown JW: Podophyllotoxins: current status and recent developments. Curr Med Chem 1998 ; 5: 205-252.
5. Xiao Z., Bastow KF, Vance JR, Sidwell R., Wang HK, Chen MS,, et al. Design, synthesis and biological evaluation of novel 4β-[(4-benzamido) amino]-4′2-O-demethyl-epipodophyllotoxin derivatives. J Med Chem 2004 ; 47: 5140-5148.
6. Marder VJ: Thrombolytic therapy. Blood Rev 2001 ; 15: 143-157.
7. Tuppurainen K.: Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity: a review with a case study: MX compounds. Chemosphere 1999 ; 38: 3015-3030.
8. Hansch C., Kurup A., Garg R., Gao H.: Chem-bioinformatics and QSAR: a review of QSAR lacking positive hydrophobic terms. Chem Rev 2001 ; 101: 619-672.
9. Livingstone DL: The characterization of chemical structures using molecular properties: a survey. J Chem Inf Comput Sci 2000 ; 40: 195-209.
10. Shi LM, Fan Y., Myers TG, Paul JN: Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues. J Chem Inf Comput Sci 1998 ; 38: 189-199.
11. Oloff S., Mailman RB, Trospha A.: Application of validated QSAR models of D1 dopaminergic antagonists for database mining. J Med Chem 2005 ; 48: 7322-7332.
12. Meneses-Marcel Y., Marrero-Ponce Y., Machado-Tugores A., Monterro-Torres DM, Pereira JA, Escario JJ,, et al. A linear discrimination analysis based virtual screening of trichomonacidal lead-like compounds: outcomes of in silico studies supported by experimental results. Bioorg Med Chem Lett 2005 ; 15: 3838-3843.
13. Santana L., Uriarte H., Gonzalez-Diaz H., Zagotto R., Soto-Otero E., Mendez-Alvarez J.: A QSAR model for in silico screening of MAO-A inhibitors: prediction, synthesis, and biological assay of novel coumarins. J Med Chem 2006 ; 49: 1149-1156.
14. Deswal S., Roy N.: Quantitative structure activity relationship studies of aryl heterocycle-based thrombin inhibitors. Eur J Med Chem 2006 ; 41: 1339-1346.
15. Gordaliza M., Castro MA, Miguel del Corral JM, San Feliciano A.: Antitumor properties of podophyllotoxin and related compound. Curr Pharm Design 2000 ; 6: 1811-1839.
16. Hitotsuyanagi Y., Fukuyo M., Kyoko T., Kobayashi M., Ozeki A., Itokawa H.,, et al. 4-Aza-2, 3-dehydro-4-deoxypodophyllotoxin: simple Aza-podophyllotoxin analogues possessing potent cytotoxicity. Bioorg Med Chem Lett 2006 ; 10: 315-317.
17. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G.,, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001 ; 12: 1643-1649.
18. Loike JD, Brewer CF, Sternlicht H., Gensler WJ, Horwitz SB: Structureactivity study of the inhibition of microtubules assembly in vitro by podophyllotoxin and its congeners. Cancer Res 1978 ; 38: 2688-2693.
19. Schrodinger LLC: Retrieved April 24, 2007, from http://www.schrodinger. com
20. ADME Works ModelBuilder, version 4.5. Fukuoka, Japan: Fujitsu Kyushu System Engineering Ltd., 2007.
21. Golbraikh A., Tropsha A.: Beware of q2! J Mol Graph Model 2002 ; 20: 269-276.
22. Roy PP, Roy K.: On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008 ; 27: 302-313.
23. Roy K., Paul S.: Exploring 2D and 3D QSARs of 2,4-diphenyl-1,3-oxazolines for ovicidal activity against Tetranychus urticae. QSAR Comb Sci 2008 ; 28: 406-425.
24. Jaiswal M., Khadikar PV, Scozzafava A., Supuran CT: Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2004 ; 14: 3283-3290.
25. Shapiro S., Guggenheim B.: Inhibition of oral bacteria by phenolic compounds: Part 1. QSAR analysis using molecular connectivity. Quant Struct Act Relat 1998 ; 17: 327-337. (Pubitemid 28401255)
26. Brewer CF, Loik JD, Horwitz SB, Sternlicht H., Gensler WJ: Conformational analysis of podophyllotoxin and its congeners: structure-activity relationship in microtubule assembly. J Med Chem 1979 ; 22: 215-221.
27. Rohrbaugh RH, Jurs PC: Description of molecular shape applied in studies of structure/activity and structure/property relationships. Anal Chim Acta 1987 ; 199: 99-109.
28. Rohrbaugh RH, Jurs PC: Molecular shape and prediction of high-performance liquid chromatographic retention indexes of polycyclic aromatic hydrocarbons. Anal Chem 1987 ; 59: 1048-1054.
29. Jurs PC, Hasan MN, Hansen PJ, Rohrbaugh RH: Physical Property Prediction in Organic Chemistry. Berlin: Springer-Verlag, 1988: 209-233.